Primary endpoint: proportion of patients maintaining VA at 52 weeks compared with baseline^3,4

• Comparable VA gains were achieved with EYLEA 2 mg vs. ranibizumab^1,2

Mean change in BCVA from baseline to week 96^3,4

Adapted from Heler JS, et al, 2012 & Schmidt-Erfurth U, et al. 2014

In Year 2, EYLEA 2 mg dosing switched from Q8 to ‘capped PRN’ up to Q12, based on individual response:^3,4

• Extended dosing intervals achieved during Year 2 in 84.1% of patients^3,4
• Mean number of injections at Week 96 was 11.2 with EYLEA 2 mg and 16.5 with ranibizumab^3,4

*48% (247/511) of patients in the Q8 arm received 3 injections or fewer (Q12) in Year 2⁹

^†Please see the EYLEA 2 mg Summary of Product Characteristics for full details of the licensed posology. 
^‡The dosing regimen for ranibizumab used in the VIEW trial programme does not represent its current recommended treatment frequency, which varies according to response.^3,9 Please consult the ranibizumab Summary of Product Characteristics for further information.

Primary endpoint: mean change in BCVA (ETDRS letters) from baseline to Week 52 with EYLEA 2 mg⁵*

Mean change in BCVA from baseline to Week 96

Adapted from Ohji M, et al. 2020.

*In ALTAIR, T&E was initiated after 3 monthly loading doses and a dose at Week 16.⁵ Please see the EYLEA 2 mg Summary of Product Characteristics for full details of the licensed posology.

Over 96 weeks of treatment, patients on EYLEA 2 mg required just 10.4 injections on average:⁵

• The mean number of injections at Week 52 was 7.2 for the 2-week adjustment group and 6.9 for the 4-week adjustment group
• The mean number of injections at Week 96 was 10.4 for both the 2-week and 4-week adjustment groups⁵

Primary endpoint: mean change in BCVA (ETDRS letters) from randomisation (Week 16) to Week 104 with EYLEA 2 mg⁶*

Adapted from Mitchell P, et al. 2021.

Per protocol set. Data from the graph above includes all patients who were allocated to each group, regardless of whether they extended or not.⁶

In the early-start T&E group, injection intervals could be extended by 2-week increments after the dose at Week 16. In the late-start T&E group, EYLEA 2 mg was administered every 8 weeks until Week 52, after which the injection interval could be extended by 2-week increments.^6‡

Early-start T&E with EYLEA 2 mg was non-inferior to late-start T&E for mean change in BCVA from Week 16–104 (p=0.0162).⁶

• The mean number of injections at Week 52 and Week 104 was 7.1 and 12.0 for early-start T&E and 8.0 and 13.0 for late-start T&E, respectively

*Analyses were conducted as a LOCF from the per-protocol set. Intervals >16 weeks were considered minor deviations and were included in the per-protocol set. In ARIES, early-start T&E was initiated after 3 monthly loading doses and a dose at Week 16; late-start T&E initiated after 1 year of fixed dosing at Q8 (following 3 monthly loading doses and a dose at Week 16).^6
†After 3 initial monthly doses, the EYLEA 2 mg treatment interval is extended to 2 months. The treatment interval can then be further extended up to 16 weeks using proactive T&E dosing.^1
‡In ARIES, early-start T&E was initiated after 3 monthly loading doses and a dose at Week 16; late-start T&E was initiated after 1 year of fixed dosing at Q8 (following 3 monthly loading doses and a dose at Week 16).⁶

Primary outcome: proportion of eyes achieving at least one Q12 retreatment interval in first 2 years⁷

Mean VA (ETDRS letters) through Year 2⁷

Adapted from Fu DJ, et al. 2023.